ImmunoGen, Inc. Waits for Data

Investors eagerly await data from the biotech's phase 3 trial, but there will be some earlier-sta...

Why ImmunoGen Fell 15% Today

ImmunoGen's shares are falling after its investor conference last week and amid an industry wide ...

ImmunoGen, Inc. Pushes Forward

With just $4.2 million in royalties from Roche's Kadcyla, investors need to be focused on ImmunoG...

The Fool Looks Ahead

Let's look at the stocks that will be making news in the week ahead.

This Week in Biotech

An FDA approval, a company more than doubling in value following an FDA advisory panel decision, ...

This Week in Biotech

Two positive clinical studies, a partial clinical hold by the FDA, a scrapped phase 2 study, and ...

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.